NASDAQ · AIMDW
Healthcare · Biotechnology
$0.08
Down-$0.00 (-5.12%)
Updated Sep 13, 2026, 9:00 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 8 trading sessions · Daily adjusted prices
AIMDW closed at $0.08 after 8 trading sessions, down 19.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $0.0778 | $0.0801 | $0.0776 | $0.0801 | 1.02K |
| Sep 8, 2026 | $0.074 | $0.082 | $0.074 | $0.0801 | 3.66K |
| Sep 4, 2026 | $0.0899 | $0.0899 | $0.0899 | $0.0899 | 103 |
| Sep 3, 2026 | $0.074 | $0.074 | $0.074 | $0.074 | 4.52K |
| Sep 2, 2026 | $0.058 | $0.0899 | $0.058 | $0.074 | 2.06K |
| Aug 20, 2026 | $0.066 | $0.0839 | $0.063 | $0.0832 | 2.15K |
| Aug 19, 2026 | $0.07 | $0.0973 | $0.066 | $0.0973 | 725 |
| Aug 18, 2026 | $0.1034 | $0.1035 | $0.0701 | $0.0997 | 10.6K |
The latest Smart Investors Daily articles mentioning AIMDW.
AIMDW research
Company profile and research snapshot.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Feb 23, 2026
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced the activation of a phased industrial deployment roadmap under a strategic framework that contemplates the installation of up to 20,000
Benzinga · Feb 2, 2026
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced a technology partnership with Mirle
Yahoo · Nov 13, 2025
Digital olfactory commercialization accelerates toward 2026 scale-up, as industrial partnerships expand to six and the IP moat strengthens. World's first patented commercial AI Nose device launched, advancing SmellTech-as-a-Service adoption. SAN DIEGO, ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AIMDW.
No results
No recent SID articles mention AIMDW.
